



Norman J. Lacayo, MD

Associate Professor of Pediatrics (Hematology and Oncology)

Pediatrics - Hematology & Oncology

CLINICAL OFFICE (PRIMARY)

- **Bass Cancer Center for Childhood Cancer and Blood Diseases**

725 Welch Rd

MC 5913

Palo Alto, CA 94304

Tel (650) 497-8953 **Fax** (650) 497-8959

Bio

CLINICAL FOCUS

- Hematology/Oncology/Stem Cell Transplant, Pediatric
- Oncology (Cancer), Pediatric
- AML, childhood and adolescent/young adult
- ALL, childhood and adolescent/young adult
- lymphoblastic lymphoma, childhood
- Pediatric Hematology-Oncology

ACADEMIC APPOINTMENTS

- Associate Professor - University Medical Line, Pediatrics - Hematology & Oncology
- Member, Maternal & Child Health Research Institute (MCHRI)
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Member, Cancer Center, (2007- present)
- Myeloid Steering Committee, Children's Oncology Group, (2007- present)
- Director, Pediatric Oncology Experimental Therapeutics Investigators' Consortium [POETIC], (2019- present)

HONORS AND AWARDS

- Member, Alpha Omega Alpha (1990)
- New Approaches in Pediatric Myeloid Leukemia, V Foundation (10/09-09/12)
- Banking Acute Leukemia Specimens at Lucile Packard Children's Hospital: Hyundai Infrastructure Grant, Hyundai Foundation (10/11-09/12)
- Molecular and Pharmacologic Correlates of Acute Myeloid Leukemia in Down Syndrome, NIH ROI subcontract from Wayne State University (01/09-04/16)

PROFESSIONAL EDUCATION

- Board Certification: Pediatric Hematology-Oncology, American Board of Pediatrics (2022)
- Medical Education: University of California at San Francisco School of Medicine (1989) CA
- Internship: UCSF Medical Center (1990) CA
- Residency: UCSF Medical Center (1992) CA
- Fellowship: Stanford University Medical Center (1995) CA
- MD, U.C., San Francisco , Medicine (1989)
- BA, U. C., Berkeley , Biochemistry (1985)

LINKS

- Research Gate: http://www.researchgate.net/profile/Norman_Lacayo/

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Pediatric Hematology/Oncology, Phase I drug studies for refractory and relapsed leukemia; genomic studies, biologic risk-stratification and treatment of acute myeloid leukemia; prediction or induction response and risk of relapse using phosphoproteomics in childhood AML; novel MRD techniques in childhood ALL.

CLINICAL TRIALS

- Collecting, Banking & Distributing Human Tissue Samples: SJCRH Tissue Resources Core Facility-TBANK, Recruiting
- Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia, Recruiting
- Phase I GD2 CAR T Cells for H3K27M-mutant Diffuse Midline Glioma (DMG), Recruiting
- Phase I Niclosamide (ANA001) in Pediatric & Young Adult Patients w/ Relapsed and Refractory AML, Recruiting
- Phase I PARP Inhibitor Talazoparib in Combination with Chemotherapy in Relapsed Pediatric AML, Recruiting
- Phase II Inotuzumab Ozogamicin in Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia(B-ALL), Recruiting
- EAP for SNDX-5613 in R/R Acute Leukemias w/ Genetic Alterations Associated w/ HOXA Overexpression, Not Recruiting
- Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects, Not Recruiting
- Phase 1 Venetoclax +Navitoclax &Chemo in Relapsed/Refractory ALL or Lymphoblastic Lymphoma, Not Recruiting
- Phase I &Expansion CLR 131 in Children/Adolescents/Young Adults in Solid Tumors/Lymphoma&BrainTumors, Not Recruiting
- Phase I Carfilzomib +Cyclophosphamide +Etoposide in Relapsed and Refractory Solid Tumors & Leukemias, Not Recruiting
- Phase I CD19/CD22 Chimeric Antigen Receptor T Cells in Peds Recurrent/Refractory B Cell Malignancies, Not Recruiting
- Phase I Nilotinib in Children with Philadelphia Chromosome-positive (Ph+) CML or ALL, Not Recruiting
- Phase I Panobinostat in Combo w/ Fludarabine & Cytarabine in Pediatric Refractory/Relapsed AML / MDS, Not Recruiting
- Phase I Venetoclax in Combo w/ Chemotherapy in Pediatric Refractory /Relapsed Acute Myeloid Leukemia, Not Recruiting
- Phase I/II Atezolizumab (MPDL3280A) in Pediatric & Young Adults w/ Previously Tx Solid Tumors, Not Recruiting
- Phase I/II Idasanutlin +/- Chemotherapy OR Venetoclax in Relapsed/Refractory AL or Solid Tumors, Not Recruiting
- Phase I/II Oral TRK Inhibitor Larotrectinib in Pediatric Advanced Solid / Primary CNS Tumors, Not Recruiting
- Phase I/II Total Therapy for Infants with Acute Lymphoblastic Leukemia (ALL) I, Not Recruiting
- Phase II Epigenetic Priming in Newly Diagnosed Acute Myeloid Leukemia, Not Recruiting
- Phase II Lenalidomide (Revlimid®) in Peds with Relapsed or Refractory Acute Myeloid Leukemia, Not Recruiting

- Phase III Nivolumab in Combo w/ Chemo-Immunotherapy in Newly Dx Primary Mediastinal B-cell Lymphoma, Not Recruiting
- Phase III Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome, Not Recruiting
- POE-16: Phase I/II Neratinib in Pediatric Patients with Relapsed or Refractory Solid Tumors, Not Recruiting
- Total Therapy Study XVII (TOTXVII) in Newly Diagnosed Acute Lymphoblastic Leukemia and Lymphoma, Not Recruiting

Publications

PUBLICATIONS

- **Dendritic cell dysfunction predicts adverse prognosis in high-risk acute lymphoblastic leukemia**
Kumar, A., Hamane, K., Duault, C., Lima-Junior, J., Jung, D., Qin, H., Salcido, S., Huang, M., Guo, X., Khani, A., Ortiz, A., Ghoda, L., Marcucci, et al
AMER ASSOC CANCER RESEARCH.2026
- **Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 study.** *The Lancet. Haematology*
Gruber, T. A., Jeha, S., Deyell, R. J., Lewis, V., Chang, B. H., Lowe, E. J., Frediani, J., Vezina, C., Michon, B., Richards, M., Breese, E. H., Tran, T. H., Lacayo, et al
2026
- **DHODH as a Targetable Metabolic Achilles' Heel for chemo-resistant B-ALL.** *Blood*
Liu, Y., Jiang, H., Liu, J., Stuani, L., Merchant, M. J., Jager, A., Koladiya, A., Chang, T. C., Domizi, P., Sarno, J., Wang, A., Keyes, T., Jedoui, et al
2026
- **Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukemia: A multi-center phase II expansion study**
Daniels, K., Pounds, S., Wu, H., Wang, L., Mehr, C., Alexander, T., Budhraj, A., Wolf, J., Westover, T., Mead, P., Lacayo, N., Pui, C., Opferman, et al
ELSEVIER.2025: 649
- **Tumor-induced dendritic cell dysfunction impairs T-cell proliferation and confers poor prognosis in high-risk acute lymphoblastic leukemia**
Kumar, A., Hamane, K., Duault, C., Lima-Junior, J., Jung, D., Qin, H., Salcido, S., Huang, M., Guo, X., Khani, A., Ortiz, A., Ghoda, L., Marcucci, et al
ELSEVIER.2025: 5138-5139
- **Pre-transplant CAR T-cell therapy is associated with inferior survival and increased non-relapse mortality in pediatric B-ALL: A single-center retrospective analysis**
Chok, R., Huang, M., Aftandilian, C., Schultz, L., Shyr, D., Lacayo, N., Shah, A., Saab, R., Gruber, T., Mackall, C., Bertaina, A., Davis, K., Klein, et al
ELSEVIER.2025: 6077-6078
- **Epigenetic priming improves survival for pediatric Acute Myeloid Leukemia: Results from the multicenter randomized AML16 trial**
Gruber, T., Pounds, S., Lacayo, N., Heym, K., Henry, M., Degar, B., Schiff, D., Razzaqi, F., Frediani, J., Milanovich, S., McNeer, J., Wu, H., Patibandla, et al
ELSEVIER.2025: 3446-3447
- **Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition.** *Blood neoplasia*
Sharma, R., Zhang, C., Shah, R., Frigault, M. M., Johnson, A. J., Mangum, D. S., Maese, L. D., Lacayo, N. J., Narendran, A.
2025; 2 (4): 100148
- **A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors.** *Cancers*
Boklan, J., Langevin, A. M., Bielasowicz, K., Neville, K., Trippett, T., Brown, V., DuBois, S. G., Eshun, F., Gelfond, J., Zomet, A., Narendran, A., Lacayo, N. J.
2025; 17 (17)
- **Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Inaba, H., Teachey, D., Annesley, C., Batra, S., Beck, J., Colace, S., Cooper, S., Dallas, M., Oliveira, S. D., Kelly, K., Kitko, C., Kohorst, M., Kutny, et al
2025; 23 (2): 41-62
- **Uridine Metabolism as a Targetable Metabolic Achilles' Heel for chemo-resistant B-ALL.** *bioRxiv : the preprint server for biology*

- Liu, Y., Jiang, H., Liu, J., Stuani, L., Merchant, M., Jager, A., Koladiya, A., Chang, T. C., Domizi, P., Sarno, J., Keyes, T., Jedoui, D., Wang, et al
2025
- **Safety and Feasibility of Blinatumomab As Frontline Therapy for Pediatric Patients with B-Acute Lymphoblastic Leukemia and Lymphoma: St. Jude Total Therapy Study XVII**
Duffy, C., Dang, E., Yinmei, Z., Bell, J., Bhakta, N., Henry, M., Heym, K., Jeha, S., Lacayo, N. J., Karol, S. E., Khaw, S., Ribeiro, R. C., Schiff, et al
ELSEVIER.2024: 4208-4209
 - **Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Marrero, R. J., Wu, H., Cao, X., Parcha, P. K., Elsayed, A. H., Inaba, H., Kuo, D. J., Degar, B. A., Heym, K., Taub, J. W., Lacayo, N., Pui, C., Ribeiro, et al
2024
 - **AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML.** *Leukemia*
Sayitoglu, E. C., Luca, B. A., Boss, A. P., Thomas, B. C., Freeborn, R. A., Uyeda, M. J., Chen, P. P., Nakauchi, Y., Waichler, C., Lacayo, N., Bacchetta, R., Majeti, R., Gentles, et al
2024
 - **Pharmacogenomics, Race, and Treatment Outcome in Pediatric Acute Myeloid Leukemia.** *JAMA network open*
Lamba, J. K., Marrero, R., Wu, H., Cao, X., Parcha, P. K., Karol, S. E., Inaba, H., Kuo, D. J., Degar, B. A., Heym, K., Taub, J. W., Lacayo, N. J., Pui, et al
2024; 7 (5): e2411726
 - **Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy.** *Frontiers in immunology*
Johns, C., Erickson, C., Jacobs, A., Moon, J., Baggott, C., Dagher, R., Nadel, H., Balagtas, J., Aftandilian, C., Ramakrishna, S., Lacayo, N., Davis, K. L., Stieglitz, et al
2024; 15: 1423487
 - **Intensification of Therapy and Pharmacogenetic Personalization Mitigate Racial Disparities in Pediatric Acute Myeloid Leukemia Outcomes**
Lamba, J. K., Marrero, R. J., Wu, H., Cao, X., Parcha, P., Karol, S. E., Inaba, H., Kuo, D., Degar, B., Heym, K., Taub, J., Lacayo, N. J., Pui, et al
AMER SOC HEMATOLOGY.2023
 - **Targeting CDK9 in KMT2A-Rearranged Infant Leukemia: Evidence for Activity and Drug Synergy with Enitociclib**
Sharma, R., Frigault, M. M., Johnson, A. J., Izumi, R., Hamdy, A., Birkett, J., Stelte-Ludwig, B., Maese, L., Lacayo, N. J., Narendran, A.
AMER SOC HEMATOLOGY.2023
 - **Uridine Synthesis Is the Metabolic Vulnerability in Relapse-Associated B-ALL Cells with Active Pre-BCR Signaling**
Liu, Y., Jiang, H., Stuani, L., Sarno, J., Domizi, P., Merchant, M., Jedoui, D., Jager, A., Huang, M., Lacayo, N. J., Sakamoto, K. M., Ye, J., Davis, et al
AMER SOC HEMATOLOGY.2023
 - **Outcome of Infants Treated on Total Therapy for Infants with Acute Lymphoblastic Leukemia I: Results from a Non-Randomized Multi-Center Study**
Gruber, T. A., Huang, M., Jeha, S., Deyell, R. J., Lewis, V. A., Chang, B. H., Lowe, E. J., Frediani, J., Vezina, C., Michon, B., Gossai, N., Breese, E. H., Thai Hoa Tran, et al
AMER SOC HEMATOLOGY.2023
 - **POE14-01: A PHASE I STUDY OF CARFILZOMIB IN COMBINATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE FOR CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH RELAPSED/REFRACTORY LEUKEMIAS OR SOLID TUMORS**
Boklan, J., Narendran, A., Bielamowicz, K., Trippett, T., Brown, V., Dubois, S., Eshun, F., Gelfond, J., Zomet, A., Lacayo, N., Langevin, A.
WILEY.2023: S117-S118
 - **A NOVEL ANTI-CANCER VACCINE APPROACH FOR THE EFFECTIVE TREATMENT OF REFRACTORY LEUKEMIA IN CHILDREN**
Tran, S., Sipila, P., Zhang, C., Maese, L., Lacayo, N., Narendran, A.
WILEY.2023: S145-S146
 - **Epigenetic Profiling of PTPN11 Mutant JMML Hematopoietic Stem and Progenitor Cells Reveals an Aberrant Histone Landscape.** *Cancers*
Sinha, R., Dvorak, M., Ganesan, A., Kalesinskas, L., Niemeyer, C. M., Flotho, C., Sakamoto, K. M., Lacayo, N., Patil, R. V., Perriman, R., Cepika, A. M., Liu, Y. L., Kuo, et al
2023; 15 (21)

- **The Tomato Brown Rugose Fruit Virus Movement Protein Gene Is a Novel Microbial Source Tracking Marker.** *Applied and environmental microbiology*
Natarajan, A., Fremin, B. J., Schmidtke, D. T., Wolfe, M. K., Zlitni, S., Graham, K. E., Brooks, E. F., Severyn, C. J., Sakamoto, K. M., Lacayo, N. J., Kuersten, S., Koble, J., Caves, et al
2023: e0058323
- **Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia.** *Journal for immunotherapy of cancer*
Kumar, A., Taghi Khani, A., Duault, C., Aramburo, S., Sanchez Ortiz, A., Lee, S. J., Chan, A., McDonald, T., Huang, M., Lacayo, N. J., Sakamoto, K. M., Yu, J., Hurtz, et al
2023; 11 (5)
- **Tomato brown rugose fruit virus Mo gene is a novel microbial source tracking marker.** *bioRxiv : the preprint server for biology*
Natarajan, A., Fremin, B. J., Schmidtke, D. T., Wolfe, M. K., Zlitni, S., Graham, K. E., Brooks, E. F., Severyn, C. J., Sakamoto, K. M., Lacayo, N. J., Kuersten, S., Koble, J., Caves, et al
2023
- **Menin inhibitors as targeted therapeutics in KMT2a rearranged infant leukemia and the identification of effective treatment combinations.**
Sharma, R., Zhang, C., Maese, L., Lacayo, N., Narendran, A.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Cytoflin enables integrated analysis of public mass cytometry datasets using generalized anchors.** *Nature communications*
Lo, Y., Keyes, T. J., Jager, A., Sarno, J., Domizi, P., Majeti, R., Sakamoto, K. M., Lacayo, N., Mullighan, C. G., Waters, J., Sahaf, B., Bendall, S. C., Davis, et al
2022; 13 (1): 934
- **GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity** *CANCER CELL*
Heitzeneder, S., Bosse, K. R., Zhu, Z., Zhelev, D., Majzner, R. G., Radosevich, M. T., Dhingra, S., Sotillo, E., Buongervino, S., Pascual-Pasto, G., Garrigan, E., Xu, P., Huang, et al
2022; 40 (1): 53-+
- **GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.** *Cancer cell*
Heitzeneder, S., Bosse, K. R., Zhu, Z., Zhelev, D., Majzner, R. G., Radosevich, M. T., Dhingra, S., Sotillo, E., Buongervino, S., Pascual-Pasto, G., Garrigan, E., Xu, P., Huang, et al
1800
- **Comparison of the Transcriptomic Signatures in Pediatric and Adult CML.** *Cancers*
Youn, M., Smith, S. M., Lee, A. G., Chae, H., Spiteri, E., Erdmann, J., Galperin, I., Jones, L. M., Donato, M., Abidi, P., Bittencourt, H., Lacayo, N., Dahl, et al
1800; 13 (24)
- **Identification and in vitro validation of neoantigens for immune activation against high-risk pediatric leukemia cells.** *Human vaccines & immunotherapeutics*
Thakur, S., Jain, M., Zhang, C., Major, C., Bielamowicz, K. J., Lacayo, N. J., Vaske, O., Lewis, V., Murguia-Favela, L., Narendran, A.
2021: 1-5
- **A comprehensive circulating tumor DNA assay for detection of translocation and copy number changes in pediatric sarcomas.** *Molecular cancer therapeutics*
Shah, A. T., Azad, T. D., Breese, M. R., Chabon, J. J., Hamilton, E. G., Straessler, K., Kurtz, D. M., Leung, S. G., Spillinger, A., Liu, H., Behroozfard, I. H., Wittber, F. M., Hazard, et al
2021
- **Activated Natural Killer Cells Predict Poor Clinical Prognosis in High-risk B- and T- cell Acute Lymphoblastic Leukemia.** *Blood*
Duault, C., Kumar, A., Taghi Khani, A., Lee, S. J., Yang, L., Huang, M., Hurtz, C., Manning, B., Ghoda, L. Y., McDonald, T., Lacayo, N. J., Sakamoto, K. M., Carroll, et al
2021
- **Engineered Type 1 Regulatory T Cells Have a Cytotoxic Profile and Kill Pediatric Acute Myeloid Leukemia Cells**
Sayitoglu, E., Uyeda, M., Liu, J. M., Cieniewicz, B., Chen, P., Lacayo, N., Cepika, A., Roncarolo, M.
CELL PRESS.2021: 317

- **Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.** *Cancer discovery*
Pullarkat, V. A., Lacayo, N. J., Jabbour, E., Rubnitz, J. E., Bajel, A., Laetsch, T. W., Leonard, J., Colace, S. I., Khaw, S. L., Fleming, S. A., Mattison, R. J., Norris, R., Opferman, et al
2021
- **Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia.** *Cancer*
Karol, S. E., Cooper, T. M., Mead, P. E., Crews, K. R., Panetta, J. C., Alexander, T. B., Taub, J. W., Lacayo, N. J., Heym, K. M., Kuo, D. J., Schiff, D. E., Bhojwani, D., Ge, et al
2020
- **Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.** *Cell*
Hoshino, A., Kim, H. S., Bojmar, L., Gyan, K. E., Cioffi, M., Hernandez, J., Zambirinis, C. P., Rodrigues, G., Molina, H., Heissel, S., Mark, M. T., Steiner, L., Benito-Martin, et al
2020
- **Integrative analysis of whole-genome and RNA sequencing in high-risk pediatric malignancies**
Shah, A. T., Breese, M. R., Lee, A. G., Martell, H. J., Tanasa, B., Leung, S. G., Spillingeer, A., Liu, H., Behroozfard, I., Phuong Dinh, Hazard, F. K., Cho, S., Rangaswami, A., et al
AMER ASSOC CANCER RESEARCH.2020: 90–91
- **Comparative gene expression analysis for identification and prioritization of therapeutic targets in a cohort of childhood cancers**
Sanders, L. M., Lyle, A., Beale, H. C., Kephart, E., Learned, K., Peralez, J., Lacayo, N., Rangaswami, A., Spunt, S. L., Bjork, I., Haussler, D., Salama, S. R., Vaske, et al
AMER ASSOC CANCER RESEARCH.2020: 66
- **Delayed cancer diagnoses and high mortality in children during the COVID-19 pandemic.** *Pediatric blood & cancer*
Ding, Y., Ramakrishna, S., Long, A. H., Phillips, C. A., Montiel-Esparza, R., Diorio, C. J., Bailey, L. C., Maude, S. L., Aplenc, R., Batra, V., Reilly, A. F., Rheingold, S. R., Lacayo, et al
2020: e28427
- **Metabolomics in acute myeloid leukemia.** *Molecular genetics and metabolism*
Wojcicki, A. V., Kasowski, M. M., Sakamoto, K. M., Lacayo, N.
2020
- **Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.** *The Lancet. Oncology*
Karol, S. E., Alexander, T. B., Budhraj, A., Pounds, S. B., Canavera, K., Wang, L., Wolf, J., Klco, J. M., Mead, P. E., Das Gupta, S., Kim, S. Y., Salem, A. H., Palenski, et al
2020
- **Repurposing Drugs for Acute Myeloid Leukemia: A Worthy Cause or a Futile Pursuit?** *Cancers*
Wojcicki, A. V., Kadapakkam, M., Frymoyer, A., Lacayo, N., Chae, H., Sakamoto, K. M.
2020; 12 (2)
- **EPIGENETIC TARGETING OF TERT-ASSOCIATED GENE EXPRESSION SIGNATURE IN HUMAN NEUROBLASTOMA WITH TERT OVEREXPRESSION.** *Cancer research*
Huang, M. n., Zeki, J. n., Sumarsono, N. n., Coles, G. L., Taylor, J. S., Danzer, E. n., Bruzoni, M. n., Hazard, F. K., Lacayo, N. J., Sakamoto, K. M., Dunn, J. C., Spunt, S. L., Chiu, et al
2020
- **Genomic stability at the coding regions of the multidrug transporter gene ABCB1: insights into the development of alternative drug resistance mechanisms in human leukemia cells.** *Cancer drug resistance (Alhambra, Calif.)*
Chen, K. G., Duran, G. E., Mogul, M. J., Wang, Y. C., Ross, K. L., Jaffrezou, J., Huff, L. M., Johnson, K. R., Fojo, T., Lacayo, N. J., Sikic, B. I.
2020; 3: 959-979
- **Engineered type 1 regulatory T cells designed for clinical use kill primary pediatric acute myeloid leukemia cells** *Haematologica*
Cieniewicz, B., Uyeda, M. J., Chen, P. P., Sayitoglu, E. C., Liu, J. M., Andolfi, G., Greenthal, K., Bertaina, A., Gregori, S., Bacchetta, R., Lacayo, N. J., Cepika, A., Roncarolo, et al
2020

- **RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit.** *Oncotarget*
Chae, H. D., Dutta, R. n., Tiu, B. n., Hoff, F. W., Accordi, B. n., Serafin, V. n., Youn, M. n., Huang, M. n., Sumarsono, N. n., Davis, K. L., Lacayo, N. J., Pigazzi, M. n., Horton, et al
2020; 11 (25): 2387–2403
- **Pediatric Acute Lymphoblastic Leukemia, Version 2.2020** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Brown, P., Inaba, H., Annesley, C., Beck, J., Colace, S., Dallas, M., DeSantes, K., Kelly, K., Kitko, C., Lacayo, N., Larrier, N., Maese, L., Mahadeo, et al
2020; 18 (1): 81–112
- **Establishing a Novel in Vitro Informed Precision Clinical Trial Pathway for Refractory Pediatric Leukemia**
Zhang, C., Sharma, R., Satbir, T., Cheney, A., Vaske, O., Sanders, L., Boklan, J., Lewis, V. A., Anderson, R., Kovalchuk, O., Lacayo, N. J., Narendran, A., Bielamowicz, et al
AMER SOC HEMATOLOGY.2019
- **Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma**
Lacayo, N. J., Pullarkat, V. A., Stock, W., Jabbour, E., Bajel, A., Rubnitz, J., Leonard, J., Mullighan, C. G., Khaw, S., Vear, S. I., Opferman, J. T., Salem, A., Schmidt, et al
AMER SOC HEMATOLOGY.2019
- **Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia**
Karol, S. E., Alexander, T., Budraja, A., Pounds, S., Canavera, K. E., Wang, L., Wolf, J., Kico, J. M., Salem, A., Palenski, T., Lacayo, N. J., Pui, C., Opferman, et al
AMER SOC HEMATOLOGY.2019
- **Comparative Tumor RNA Sequencing Analysis for Difficult-to-Treat Pediatric and Young Adult Patients With Cancer.** *JAMA network open*
Vaske, O. M., Bjork, I., Salama, S. R., Beale, H., Tayi Shah, A., Sanders, L., Pfeil, J., Lam, D. L., Learned, K., Durbin, A., Kephart, E. T., Currie, R., Newton, et al
2019; 2 (10): e1913968
- **Combination BCL-2 Inhibitor Therapy with Venetoclax and Navitoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma**
Jabbour, E., Mullighan, C. G., Pullarkat, V. A., Lacayo, N. J., Bajel, A., Rubnitz, J., Leonard, J., Khaw, S., Vear, S. I., Alexander, T., Norris, R., Salem, A., Schmidt, et al
CIG MEDIA GROUP, LP.2019: S184–S185
- **Integrative analysis of whole-genome and RNA sequencing in high-risk pediatric malignancies**
Breese, M. R., Shah, A. T., Lee, A. G., Tanasa, B., Leung, S. G., Spillinger, A., Liu, H., Behroozfard, I., Phuong Dinh, Hazard, F. K., Rangaswami, A., Spunt, S. L., Lacayo, N. J., et al
AMER ASSOC CANCER RESEARCH.2019
- **Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Rubnitz, J. E., Lacayo, N. J., Inaba, H., Heym, K., Ribeiro, R. C., Taub, J., McNeer, J., Degar, B., Schiff, D., Yeoh, A. E., Coustan-Smith, E., Wang, L., Triplett, et al
2019: JCO1900327
- **Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.**
Karol, S. E., Alexander, T., Das Gupta, S., Pounds, S. B., Canavera, K., Kico, J. M., Lacayo, N., Pui, C., Opferman, J. T., Rubnitz, J. E.
AMER SOC CLINICAL ONCOLOGY.2019
- **A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.** *Journal for immunotherapy of cancer*
Nguyen, R., Wu, H., Pounds, S., Inaba, H., Ribeiro, R. C., Cullins, D., Rooney, B., Bell, T., Lacayo, N. J., Heym, K., Degar, B., Schiff, D., Janssen, et al
2019; 7 (1): 81
- **Comparative RNA-seq analysis aids in diagnosis of a rare pediatric tumor.** *Cold Spring Harbor molecular case studies*
Sanders, L. M., Rangaswami, A. n., Bjork, I. n., Lam, D. L., Beale, H. C., Kephart, E. T., Durbin, A. n., Learned, K. n., Currie, R. n., Lyle, A. G., Pfeil, J. n., Shah, A. T., Lee, et al

2019; 5 (5)

- **Tracking Cell Transplants in Femoral Osteonecrosis with Magnetic Resonance Imaging: A Proof-of-Concept Study in Patients** *CLINICAL CANCER RESEARCH*
Theruvath, A. J., Nejadnik, H., Muehe, A. M., Gassert, F., Lacayo, N. J., Goodman, S. B., Daldrup-Link, H. E.
2018; 24 (24): 6223–29
- **Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells**
Chae, H., Murphy, L. C., Donato, M., Lee, A. G., Sweet-Cordero, E., Abidi, P., Bittencourt, H., Lacayo, N. J., Dahl, G., Aftandilian, C., Davis, K. L., Huang, M., Sumarsono, et al
AMER SOC HEMATOLOGY.2018
- **Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma**
Alexander, T., Lacayo, N. J., Pullarkat, V. A., Jabbour, E. J., Khaw, S., Mullighan, C. G., Bajel, A., Leonard, J., Norris, R., Rubnitz, J., Vear, S. I., Schmidt, M., Tong, et al
AMER SOC HEMATOLOGY.2018
- **Tracking Cell Transplants in Femoral Osteonecrosis with Magnetic Resonance Imaging: A Proof of Concept Study in Patients.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Theruvath, A. J., Nejadnik, H., Muehe, A. M., Gassert, F., Lacayo, N. J., Goodman, S. B., Daldrup-Link, H. E.
2018
- **Safety and Efficacy of the BCL Inhibitors Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed/ Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma**
Hantel, A., Wynne, J., Lacayo, N., Khaw, S., Rubnitz, J., Mullighan, C., Schmidt, M., Zhou, Y., Ross, J. A., Rosenwinkel, L., Kim, S., Jabbour, E., Alexander, et al
CIG MEDIA GROUP, LP.2018: S184–S185
- **Open-label, dose-escalation, phase 1 study of venetoclax in combination with navitoclax and chemotherapy in patients with relapsed acute lymphoblastic leukemia.**
Alexander, T., Khaw, S., Rubnitz, J. E., Vear, S. I., Lacayo, N., Schmidt, M., Tong, B., Rosenwinkel, L., Bensman, L., Verdugo, M., Kim, S., Jabbour, E., Stock, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse.** *Nature medicine*
Good, Z., Sarno, J., Jager, A., Samusik, N., Aghaeepour, N., Simonds, E. F., White, L., Lacayo, N. J., Fantl, W. J., Fazio, G., Gaipa, G., Biondi, A., Tibshirani, et al
2018; 24 (4): 474–83
- **Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse** *NATURE MEDICINE*
Good, Z., Sarno, J., Jager, A., Samusik, N., Aghaeepour, N., Simonds, E. F., White, L., Lacayo, N. J., Fantl, W. J., Fazio, G., Gaipa, G., Biondi, A., Tibshirani, et al
2018; 24 (4): 474+
- **The Significance of Dim Cytoplasmic CD3 Expression in Acute Myeloid Leukemia: A Long-Term Retrospective Study Identifies an Association with Acute Promyelocytic Leukemia with FLT3-ITD Mutations**
Kumar, J., Nagy, A., Lacayo, N., Gotlib, J., Zehnder, J. L., Ohgami, R.
NATURE PUBLISHING GROUP.2018: 529
- **The Significance of Dim Cytoplasmic CD3 Expression in Acute Myeloid Leukemia: A Long-Term Retrospective Study Identifies an Association with Acute Promyelocytic Leukemia with FLT3-ITD Mutations**
Kumar, J., Nagy, A., Lacayo, N., Gotlib, J., Zehnder, J. L., Ohgami, R.
NATURE PUBLISHING GROUP.2018: 529
- **Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways** *ONCOTARGET*
Chae, H., Cox, N., Dahl, G. V., Lacayo, N. J., Davis, K. L., Capolicchio, S., Smith, M., Sakamoto, K. M.
2018; 9 (4): 4301–17
- **Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.** *Blood*

Taub, J. W., Berman, J. N., Hitzler, J. K., Sorrell, A. D., Lacayo, N. J., Mast, K., Head, D., Raimondi, S., Hirsch, B., Ge, Y., Gerbing, R. B., Wang, Y., Alonzo, et al
2017

- **The Significance of CD56 Expression and the RAM Immunophenotype, a Recurrent Immunophenotype Seen in Children, in Adult Acute Myeloid Leukemia**
Lazzareschi, D., Cherry, A., Zehnder, J., Gotlib, J., Arber, D. A., Lacayo, N., Ohgami, R.
NATURE PUBLISHING GROUP.2017: 358A–359A
- **The Significance of Morphologic Dysplasia in 432 Cases of Acute Lymphoblastic Leukemia and Acute Leukemia of Ambiguous Lineage: Correlation with Cytogenetic, Immunophenotypic, and Molecular Findings**
Segal, J., Dahl, G., Lacayo, N., Gotlib, J., Ohgami, R.
NATURE PUBLISHING GROUP.2017: 376A
- **A Detailed Multi parameter Flow Cytometry Study of 365 Cases of B-Lymphoblastic Leukemia with Subtyping According to the 2016 WHO: A Single Institutional Study**
Segal, J., Lacayo, N., Gotlib, J., Ohgami, R.
NATURE PUBLISHING GROUP.2017: 376A
- **Detailed Multiparameter Flow Cytometry Study of 365 Cases of B-Lymphoblastic Leukemia with Subtyping According to the 2016 WHO: A Single Institutional Study**
Segal, J., Lacayo, N., Gotlib, J., Ohgam, R.
NATURE PUBLISHING GROUP.2017: 376A
- **The Significance of Morphologic Dysplasia in 432 Cases of Acute Lymphoblastic Leukemia and Acute Leukemia of Ambiguous Lineage: Correlation with Cytogenetic, Immunophenotypic, and Molecular Findings**
Segal, J., Dahl, G., Lacayo, N., Gotlib, J., Ohgami, R.
NATURE PUBLISHING GROUP.2017: 376A
- **The Significance of CD56 Expression and the RAM Immunophenotype, a Recurrent Immunophenotype Seen in Children, in Adult Acute Myeloid Leukemia**
Lazzareschi, D., Cherry, A., Zehnder, J., Gotlib, J., Arber, D. A., Lacayo, N., Ohgami, R.
NATURE PUBLISHING GROUP.2017: 358A–359A
- **Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia** *JOURNAL OF CLINICAL ONCOLOGY*
Alexander, T. B., Lacayo, N. J., Choi, J. K., Ribeiro, R. C., Pui, C., Rubnitz, J. E.
2016; 34 (34): 4094-?
- **Small molecule inhibition of cAMP response element binding protein in human acute myeloid leukemia cells.** *Leukemia*
Mitton, B., Chae, H., Hsu, K., Dutta, R., Aldana-Masangkay, G., FERRARI, R., Davis, K., Tiu, B. C., Kaul, A., Lacayo, N., Dahl, G., Xie, F., Li, et al
2016
- **Replication factor C3 is a CREB target gene that regulates cell cycle progression through the modulation of chromatin loading of PCNA** *LEUKEMIA*
Chae, H., Mitton, B., Lacayo, N. J., Sakamoto, K. M.
2015; 29 (6): 1379-1389
- **Improvement in Treatment Outcome and Identification of a New Prognostic Parameter in Down Syndrome Acute Myeloid Leukemia (DS-AML): Results of the Children's Oncology Group (COG) Phase III AAML0431 Trial**
Taub, J. W., Berman, J. N., Hitzler, J. K., Sorrell, A. D., Lacayo, N. J., Mast, K., Head, D. R., Raimondi, S. C., Hirsch, B. A., Gerbing, R. B., Alonzo, T. A., Campana, D., Coustan-Smith, et al
AMER SOC HEMATOLOGY.2014
- **Altered resting state functional connectivity in young survivors of acute lymphoblastic leukemia.** *Pediatric blood & cancer*
Kesler, S. R., Gugel, M., Pritchard-Berman, M., Lee, C., Kutner, E., Hosseini, S. M., Dahl, G., Lacayo, N.
2014; 61 (7): 1295-1299
- **Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group** *BRITISH JOURNAL OF HAEMATOLOGY*
Lacayo, N. J., Alonzo, T. A., Gayko, U., Rosen, D. B., Westfall, M., Purvis, N., Putta, S., Louie, B., Hackett, J., Cohen, A. C., Cesano, A., Gerbing, R., Ravindranath, et al

2013; 162 (2): 250-262

- **Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421** *LEUKEMIA*
O'Brien, M. M., Cao, X., Pounds, S., Dahl, G. V., Raimondi, S. C., Lacayo, N. J., Taub, J., Chang, M., Weinstein, H. J., Ravindranath, Y., Inaba, H., Campana, D., Pui, et al
2013; 27 (3): 731-734
- **COMPARISON OF HIGH-THROUGHPUT SEQUENCING AND FLOW CYTOMETRY FOR MEASURING MINIMAL RESIDUAL DISEASE IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: A CHILDREN'S ONCOLOGY GROUP COHORT**
Gawad, C., Borowitz, M., Dahl, G., Devidas, M., Faham, M., Moorhead, M., Wood, B., Zheng, J., Loh, M., Lacayo, N.
SPRINGER.2013: S23-S24
- **AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin** *PLOS ONE*
Rosen, D. B., Harrington, K. H., Cordeiro, J. A., Leung, L. Y., Putta, S., Lacayo, N., Laszlo, G. S., Gudgeon, C. J., Hogge, D. E., Hawtin, R. E., Cesano, A., Walter, R. B.
2013; 8 (1)
- **Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia** *BLOOD*
Gawad, C., Pepin, F., Carlton, V. E., Klinger, M., Logan, A. C., Miklos, D. B., Faham, M., Dahl, G., Lacayo, N.
2012; 120 (22): 4407-4417
- **Comparison of High-Throughput Sequencing and Flow Cytometry for Measuring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Children's Oncology Group Cohort** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Gawad, C., Borowitz, M. J., Dahl, G. V., Devidas, M., Faham, M., Moorhead, M., Wood, B. L., Zheng, J., Loh, M. L., Lacayo, N. J.
AMER SOC HEMATOLOGY.2012
- **Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML** *LEUKEMIA RESEARCH*
Rosen, D. B., Cordeiro, J. A., Cohen, A., Lacayo, N., Hogge, D., Hawtin, R. E., Cesano, A.
2012; 36 (7): 900-904
- **Circular RNAs Are the Predominant Transcript Isoform from Hundreds of Human Genes in Diverse Cell Types** *PLOS ONE*
Salzman, J., Gawad, C., Wang, P. L., Lacayo, N., Brown, P. O.
2012; 7 (2)
- **Next-Generation Sequencing of Immunoglobulin Heavy Chain Variable Region in Diagnostic Samples of Pediatric Acute Lymphoblastic Leukemia Identifies Hundreds of Clonal Subpopulations with Multiple Immunophenotypes** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Gawad, C., Faham, M., Willis, T., Moorhead, M., Carlton, V., Zheng, J., Klinger, M., Dahl, G. V., Lacayo, N. J.
AMER SOC HEMATOLOGY.2011: 624-24
- **Dorsolateral Midbrain MRI Abnormalities and Ocular Motor Deficits Following Cytarabine-Based Chemotherapy for Acute Myelogenous Leukemia** *JOURNAL OF NEURO-OPHTHALMOLOGY*
Doan, T., Lacayo, N., Fisher, P. G., Liao, Y. J.
2011; 31 (1): 52-53
- **A pilot study of an online cognitive rehabilitation program for executive function skills in children with cancer-related brain injury** *BRAIN INJURY*
Kesler, S. R., Lacayo, N. J., Jo, B.
2011; 25 (1): 101-112
- **Single Cell Network Profiling (SCNP) Signatures Predict Response to Induction Therapy and Relapse Risk In Pediatric Patients with Acute Myeloid Leukemia: Children's Oncology Group (COG) Study POG-9421**
Lacayo, N. J., Cohen, A., Westfall, M., Lackey, A., Xin, X., Gayko, U., Putta, S., Meshinch, S., Raimondi, S. C., Alonzo, T. A., Arceci, R. J., Ravindranath, Y., Dahl, et al
AMER SOC HEMATOLOGY.2010: 420-21
- **Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial** *LANCET ONCOLOGY*
Rubnitz, J. E., Inaba, H., Dahl, G., Ribeiro, R. C., Bowman, W. P., Taub, J., Pounds, S., Razzouk, B. I., Lacayo, N. J., Cao, X., Meshinchi, S., Degar, B., Airewele, et al

2010; 11 (6): 543-552

- **Phase I Study of Valspodar (PSC-833) With Mitoxantrone and Etoposide in Refractory and Relapsed Pediatric Acute Leukemia: A Report From the Children's Oncology Group** *PEDIATRIC BLOOD & CANCER*
O'Brien, M. M., Lacayo, N. J., Lum, B. L., Kshirsagar, S., Buck, S., Ravindranath, Y., Bernstein, M., Weinstein, H., Chang, M. N., Arceci, R. J., Sikic, B. I., Dahl, G. V.
2010; 54 (5): 694-702
- **Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML** *BLOOD*
Pollard, J. A., Alonzo, T. A., Gerbing, R. B., Ho, P. A., Zeng, R., Ravindranath, Y., Dahl, G., Lacayo, N. J., Becton, D., Chang, M., Weinstein, H. J., Hirsch, B., Raimondi, et al
2010; 115 (12): 2372-2379
- **WT1 Expression at Diagnosis Does Not Predict Survival in Pediatric AML: A Report From the Children's Oncology Group** *PEDIATRIC BLOOD & CANCER*
Noronha, S. A., Farrar, J. E., Alonzo, T. A., Gerbing, R. B., Lacayo, N. J., Dahl, G. V., Ravindranath, Y., Arceci, R. J., Loeb, D. M.
2009; 53 (6): 1136-1139
- **Speeding the Flow Toward Personalized Therapy in Childhood Acute Leukemia** *PEDIATRIC BLOOD & CANCER*
Simonds, E. F., Davis, K. L., Lacayo, N. J.
2009; 53 (4): 525-526
- **Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia** *CANCER GENETICS AND CYTOGENETICS*
Schiffman, J. D., Wang, Y., McPherson, L. A., Welch, K., Zhang, N., Davis, R., Lacayo, N. J., Dahl, G. V., Faham, M., Ford, J. M., Ji, H. P.
2009; 193 (1): 9-18
- **Genomics of childhood leukemias: The virtue of complexity** *JOURNAL OF CLINICAL ONCOLOGY*
Sikic, B. I., Tibshirani, R., Lacayo, N. J.
2008; 26 (27): 4367-4368
- **Tissue microarrays from bone marrow aspirates for high-throughput assessment of immunohistologic markers in pediatric acute leukemia** *PEDIATRIC AND DEVELOPMENTAL PATHOLOGY*
Hazard, F. K., Zhao, S., Schiffman, J. D., Lacayo, N. J., Dahl, G. V., Natkunam, Y.
2008; 11 (4): 283-290
- **Acute leukemia in children** *DM DISEASE-A-MONTH*
O'Brien, M. M., Lacayo, N. J.
2008; 54 (4): 202-225
- **Molecular Inversion Probes (MIPs) identify novel areas of allelic imbalance in childhood leukemia**
Schiffman, J. D., Welch, K., Davis, R., Lacayo, N. J., Dahl, G. V., Wang, Y., Faham, M., Ford, J. M., Ji, H. P.
AMER SOC HEMATOLOGY.2007: 431A
- **The incidence and clinical significance of nucleophosmin mutations in childhood AML** *BLOOD*
Brown, P., McIntyre, E., Rau, R., Meshinchi, S., Lacayo, N., Dahl, G., Alonzo, T. A., Chang, M., Arceci, R. J., Small, D.
2007; 110 (3): 979-985
- **Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias** *JOURNAL OF CLINICAL ONCOLOGY*
Juric, D., Lacayo, N. J., Ramsey, M. C., Racevskis, J., Wiernik, P. H., Rowe, J. M., Goldstone, A. H., O'Dwyer, P. J., Paietta, E., Sikic, B. I.
2007; 25 (11): 1341-1349
- **Gene expression profiling predicts outcome in de novo acute myeloid leukemia (AML) with normal karyotype: Results of children's oncology group (COG) study POG #9421.** *48th Annual Meeting of the American-Society-of-Hematology*
Lacayo, N. J., O'Brien, M., Jain, S., Meshinchi, S., Yu, R., Juric, D., Chang, M. N., Tebshirani, R., Ravindranath, Y., Weinstein, H. J., Sikic, B. I., Van Houten Dahl, G.
AMER SOC HEMATOLOGY.2006: 542A-542A
- **Incidence and clinical significance of nucleophosmin mutations in childhood AML: A Childrens Oncology Group study.**
Brown, P., McIntyre, E., Rau, R., Alonzo, T. A., Gerbing, R., Meshinchi, S., Lacayo, N., Chang, M., Arceci, R., Small, D.

AMER SOC HEMATOLOGY.2006: 69A–70A

- **Novel allele quantification method to classify childhood leukemia.**
Schiffman, J. D., Welch, K. M., Davis, R., Van Houten Dahl, G., Lacayo, N. J., Ford, J. M.
AMER SOC HEMATOLOGY.2006: 643A–644A
- **Differential gene expression patterns and interaction networks in BCR/ABL positive and negative adult acute lymphoblastic leukemias.** *48th Annual Meeting of the American-Society-of-Hematology*
Juric, D., Lacayo, N. J., Ramsey, M. C., Racevskis, J., Wiernik, P. H., Rowe, J. M., Goldstone, A. H., O'Dwyer, P. J., Paietta, E., Sikic, B. I.
AMER SOC HEMATOLOGY.2006: 520A–520A
- **CpG island methylator phenotype and childhood leukemia** *CLINICAL CANCER RESEARCH*
Lacayo, N. J., Di Martino, J. F., Wei, M. C., Dahl, G. V.
2006; 12 (16): 4787-4789
- **Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein** *LEUKEMIA*
DiMartino, J. F., Lacayo, N. J., Varadi, M., Li, L., Saraiya, C., Ravindranath, Y., Yu, R., Sikic, B., Raimondi, S. C., Dahl, G.
2006; 20 (3): 426-432
- **Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421** *BLOOD*
Becton, D., Dahl, G. V., Ravindranath, Y., Chang, M. N., Behm, F. G., Raimondi, S. C., Head, D. R., Stine, K. C., Lacayo, N. J., Sikic, B. I., Arceci, R. J., Weinstein, H.
2006; 107 (4): 1315-1324
- **Gene expression profiling and FLT3 status correlate with outcome in de novo acute myeloid leukemia (AML) with normal karyotype: Results of children's oncology group (COG) study POG #9421.** *47th Annual Meeting of the American-Society-of-Hematology*
Lacayo, N., Meshinchi, S., Raimondi, S., Saraiya, C., O'Brien, M., Yu, R., Juric, D., Chang, M., Willman, C., Tibshirani, R., Ravindranath, Y., Sikic, B., Weinstein, et al
AMER SOC HEMATOLOGY.2005: 667A–667A
- **Improved remission induction rate of childhood AML: Preliminary results of the AML02 trial.**
Rubnitz, J., Razzouk, B., Bowman, P., Dahl, G., Lacayo, N., Taub, J., Ravindranath, Y., Meshinchi, S., Airewele, G., Lensing, S., Pounds, S., Ribeiro, R., Pui, et al
AMER SOC HEMATOLOGY.2005: 84A
- **Array CGH discovers novel genomic signatures in de novo acute myeloid leukemia (AML): Results of children's oncology group (COG) study POG #9421**
Kuo, D. J., Lacayo, N. J., Hoang, D., Juric, D., Raimondi, S. C., Chen, D., Chang, M. N., Ravindranath, Y., Weinstein, H. J., Sikic, B. I., Dahl, G. V.
AMER SOC HEMATOLOGY.2005: 777A
- **Osteonectin/SPARC is epigenetically silenced in AML with MLL gene rearrangements and selectively inhibits the growth of MLL rearranged cell lines** *46th Annual Meeting of the American-Society-of-Hematology*
DiMartino, J. F., Lacayo, N. J., Varadi, M., Ravindranath, Y., Yu, R., Sikic, B., Raimondi, S. C., Dahl, G. V.
AMER SOC HEMATOLOGY.2004: 314A–314A
- **FLT3 mutations determine the clinical outcome in children with de novo acute myelogenous leukemia (AML) and normal karyotype: Pediatric Oncology Group (POG) study # 9421.**
Lacayo, N. J., Meshinchi, S., Raimondi, S. C., Kuo, D. J., Yu, R., Chang, M. N., Willman, C. L., Tibshirani, R., Ravindranath, Y., Sikic, B. I., Weinstein, H., Dahl, G. V.
AMER SOC HEMATOLOGY.2004: 165A
- **Gene expression profiling identifies genes associated with in vitro resistance to daunorubicin and cytarabine in children with de novo acute myelogenous leukemia (AML) from the Pediatric Oncology Group (POG) study # 9421**
Kuo, D. J., Lacayo, N. J., Buck, S., Yu, R., Saraiya, C., Douglas, L., Weinstein, H., Chang, M., Willman, C. L., Tibshirani, R., Dahl, G. V., Sikic, B., Ravindranath, et al
AMER SOC HEMATOLOGY.2004: 320A
- **Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes** *BLOOD*
Lacayo, N. J., Meshinchi, S., Kinnunen, P., Yu, R., Wang, Y., Stuber, C. M., Douglas, L., Wahab, R., Becton, D. L., Weinstein, H., Chang, M. N., Willman, C. L., Radich, et al

2004; 104 (9): 2646-2654

- **Gene expression profiling (GEP) in de novo pediatric acute myeloid leukemia (AML) patients reveals a robust expression signature that correlates with *inv(16)* and *t(16;16)*.**

Lacayo, N., Kinnunen, P., Raimondi, S. C., Yu, R., Wahab, R., Stuber, C., Douglas, L., Chang, M., Willman, C. L., Ravindranath, Y., Weinstein, H., Becton, D., Behm, et al
AMER SOC HEMATOLOGY.2003: 365A

- **Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells.** *Journal of experimental therapeutics & oncology*

Lacayo, N. J., Duran, G. E., Sikic, B. I.
2003; 3 (3): 127-135

- **Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma** *GENES CHROMOSOMES & CANCER*

Chen, G. K., Lacayo, N. J., Duran, G. E., Wang, Y., Bangs, C. D., Rea, S., Kovacs, M., Cherry, A. M., Brown, J. M., Sikic, B. I.
2002; 34 (4): 372-383

- **Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia** *LEUKEMIA*

Lacayo, N. J., Lum, B. L., Becton, D. L., Weinstein, H., Ravindranath, Y., Chang, M. N., Bomgaars, L., Lauer, S. J., Sikic, B. I., Dahl, G. V.
2002; 16 (5): 920-927

- **Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia** *JOURNAL OF CLINICAL ONCOLOGY*

Dahl, G. V., Lacayo, N. J., Brophy, N., Dunussi-Joannopoulos, K., Weinstein, H. J., Chang, M. R., Sikic, B. I., Arceci, R. J.
2000; 18 (9): 1867-1875

- **Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant p-glycoprotein with deleted Phe(335)** *MOLECULAR PHARMACOLOGY*

Chen, G. K., Lacayo, N. J., Duran, G. E., Cohen, D., Sikic, B. I.
2000; 57 (4): 769-777

- **Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins** *JOURNAL OF BIOLOGICAL CHEMISTRY*

Chen, G., Duran, G. E., Steger, K. A., Lacayo, N. J., Jaffrezou, J. P., Dumontet, C., Sikic, B. I.
1997; 272 (9): 5974-5982